Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;37(7):2197-2211.
doi: 10.1007/s11011-022-00926-5. Epub 2022 Mar 3.

Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside

Affiliations
Review

Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside

Shivangi Patel et al. Metab Brain Dis. 2022 Oct.

Abstract

Schizophrenia (SZ) is a severe progressive neurodegenerative as well as disruptive behavior disorder affecting innumerable people throughout the world. The discovery of potential biomarkers in the clinical scenario would lead to the development of effective methods of diagnosis and would provide an understanding of the prognosis of the disease. Moreover, breakthrough inventions for the treatment and prevention of this mysterious disease could evolve as a result of a thorough understanding of the clinical biomarkers. In this review, we have discussed about specific biomarkers of SZ an emphasis has been laid to delineate (1) diagnostic biomarkers like neuroimmune biomarkers, metabolic biomarkers, oligodendrocyte biomarkers and biomarkers of negative and cognitive symptoms, (2) therapeutic biomarkers like various neurotransmitter systems and (3) prognostic biomarkers. All the biomarkers were evaluated in drug-naïve (at least for 4 weeks) patients in order to achieve a clear comparison between schizophrenic patients and healthy controls. Also, an attempt has been made to elucidate the potential genes which serve as predictors and tools for the determination of biomarkers and would ultimately help in the prevention and treatment of this deadly illness.

Keywords: Biomarkers; Cognition; Negative symptoms; Neurodegeneration; Neuroinflammation; Schizophrenia.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Acar E, Schenker C, Levin-Schwartz Y et al (2019) Unraveling diagnostic biomarkers of schizophrenia through structure-revealing fusion of multi-modal neuroimaging data. Front Neurosci 13. https://doi.org/10.3389/fnins.2019.00416
    1. Al-Hakeim HK, Almulla AF, Maes M (2020) The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study. Neurotox Res 37:753–771. https://doi.org/10.1007/s12640-019-00112-z - DOI - PubMed
    1. Al-Hakeim HK, Mousa RF, Al-Dujaili AH, Maes M (2021) In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy. Metab Brain Dis 36:939–955. https://doi.org/10.1007/s11011-021-00685-9 - DOI - PubMed
    1. Ayari F, Ben Chaaben A, Ben Ammar H et al (2020) Association of high-sensitivity C-reactive protein with susceptibility to Schizophrenia in Tunisian population. Encephale 46:241–247. https://doi.org/10.1016/j.encep.2019.10.001 - DOI - PubMed
    1. Brodbeck C, Presacco A, Simon JZ (2018) Neural source dynamics of brain responses to continuous stimuli: Speech processing from acoustics to comprehension. NeuroImage 172:162–174. https://doi.org/10.1016/j.neuroimage.2018.01.042 - DOI - PubMed

LinkOut - more resources